Obinutuzumab for previously untreated chronic lymphocytic leukemia

被引：2
|
作者：
不详
机构：
来源：
JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY | 2014年 / 12卷 / 04期
关键词：
D O I：
10.12788/jcso.0032
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：118 / 120
页数：3
相关论文
共 50 条
  • [21] Results of a phase II multicenter study of obinutuzumab plus bendamustine in pts with previously untreated chronic lymphocytic leukemia (CLL).
    Sharman, Jeff Porter
    Yimer, Habte Aragaw
    Boxer, Michael
    DiBella, Nicholas
    Babu, Sunil
    Li, Jia
    Mun, . . . Yong Jun
    Skettino, Sandra L.
    Danilov, Alexey Valeryevich
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] Clonal Evolution In Patients With Previously Untreated Chronic Lymphocytic Leukemia
    Parikh, Sameer A.
    Rabe, Kari G.
    Smoley, Stephanie A.
    Wiktor, Anne E.
    Hanson, Curtis A.
    Shanafelt, Tait D.
    Van Dyke, Daniel L.
    BLOOD, 2013, 122 (21)
  • [23] The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia
    Al-Sawaf, Othman
    Fuerstenau, Moritz
    Giza, Adam
    Robrecht, Sandra
    Von Tresckow, Julia
    Fink, Anna Maria
    Simon, Florian
    Tausch, Eugen
    Schneider, Christof
    Sivcheva, Liliya
    Schwarer, Anthony
    Loscertales, Javier
    Weinkove, Robert
    Strumberg, Dirk
    Kilfoyle, Allanah R.
    Juliusson, Gunnar
    Da Cunha-Bang, Caspar
    Illmer, Thomas
    Gregor, Michael
    Thornton, Patrick
    Janssens, Ann
    Tadmor, Tamar
    Lindstrom, Vesa
    Staber, Philipp Bernhard
    Levin, Mark-David
    Wendtner, Clemens-Martin
    Kreuzer, Karl-Anton
    Ritgen, Matthias
    Stilgenbauer, Stephan
    Kater, Arnon P.
    Niemann, Carsten Utoft
    Fischer, Kirsten
    Eichhorst, Barbara F.
    Hallek, Michael
    BLOOD, 2023, 142
  • [24] Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study
    Leblond, Veronique
    Aktan, Melih
    Ferra Coll, Christelle M.
    Dartigeas, Caroline
    Kisro, Jens
    Montillo, Marco
    Raposo, Joao
    Merot, Jean-Louis
    Robson, Susan
    Gresko, Ekaterina
    Bosch, Francesc
    Stilgenbauer, Stephan
    Foa, Robin
    HAEMATOLOGICA, 2018, 103 (11) : 1889 - 1898
  • [25] Phase 3 Trial of Acalabrutinib in Combination with Venetoclax, With and Without Obinutuzumab Versus Chemoimmunotherapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
    Brown, Jennifer R.
    Eichhorst, Barbara
    Ghia, Paolo
    Kater, A. P.
    Li, Jianyong
    Khurana, Sudha
    Elhamy, Mostafa
    Wang, Min Hui
    Seymour, John F.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S221 - S222
  • [26] Safety and Efficacy of Obinutuzumab Plus Fludarabine and Cyclophosphamide in Previously Untreated Patients with Chronic Lymphocytic Leukemia: Subgroup Analysis of the GREEN Study
    Leblond, Veronique
    Cantin, Guy
    Cortelezzi, Agostino
    Knauf, Wolfgang
    Tiab, Mourad
    Turgut, Mehmet
    Zaritskey, Andrey
    Merot, Jean-Louis
    Trunzer, Kerstin
    Robson, Susan
    Gresko, Ekaterina
    Stilgenbauer, Stephan
    Foa, Robin
    Bosch, Francesc
    BLOOD, 2017, 130
  • [27] U.S. Food and Drug Administration Approval: Obinutuzumab in Combination with Chlorambucil for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia
    Lee, Hyon-Zu
    Miller, Barry W.
    Kwitkowski, Virginia E.
    Ricci, Stacey
    DelValle, Pedro
    Saber, Haleh
    Grillo, Joseph
    Bullock, Julie
    Florian, Jeffry
    Mehrotra, Nitin
    Ko, Chia-Wen
    Nie, Lei
    Shapiro, Marjorie
    Tolnay, Mate
    Kane, Robert C.
    Kaminskas, Edvardas
    Justice, Robert
    Farrell, Ann T.
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2014, 20 (15) : 3902 - 3907
  • [28] OBINUTUZUMAB FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
    Rogers, K. A.
    Jones, J. A.
    DRUGS OF TODAY, 2014, 50 (06) : 407 - 419
  • [29] Venetoclax and obinutuzumab in chronic lymphocytic leukemia
    Fischer, Kirsten
    Al-Sawaf, Othman
    Fink, Anna-Maria
    Dixon, Mark
    Bahlo, Jasmin
    Warburton, Simon
    Kipps, Thomas J.
    Weinkove, Robert
    Robinson, Sue
    Seiler, Till
    Opat, Stephen
    Owen, Carolyn
    Lopez, Javier
    Humphrey, Kathryn
    Humerickhouse, Rod
    Tausch, Eugen
    Frenzel, Lukas
    Eichhorst, Barbara
    Wendtner, Clemens-M.
    Stilgenbauer, Stephan
    Langerak, Anton W.
    van Dongen, Jacque J. M.
    Boettcher, Sebastian
    Ritgen, Matthias
    Goede, Valentin
    Mobasher, Mehrdad
    Hallek, Michael
    BLOOD, 2017, 129 (19) : 2702 - 2705
  • [30] MAJIC: a phase III trial of acalabrutinib plus venetoclax versus venetoclax plus obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma
    Ryan, Christine E.
    Davids, Matthew S.
    Hermann, Richard
    Shahkarami, Mina
    Biondo, Juliana
    Abhyankar, Sarang
    Alhasani, Hasan
    Sharman, Jeff P.
    Mato, Anthony R.
    Roeker, Lindsey E.
    FUTURE ONCOLOGY, 2022, 18 (33) : 3689 - 3699
12345